A Phase 3 interventional study of Brivaracetam and Brivaracetam in Epilepsy, sponsored by UCB Pharma. Terminated at 68 sites in 6 countries. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-07-11.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.
Among the 34 studies testing brivaracetam in Epilepsy, this one is the 21st largest by enrollment, is one of 4 that started in 2008, is one of 21 in phase 3, and was the 11th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Belgium, Czechia and 8 more countries
Ages 1 mo+
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 16 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2008.
This study's enrollment of 62 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 34 interventional studies. Of the 31 that completed or were terminated, 23 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 72nd largest by enrollment of the 116 interventional ones that give a count, is one of 13 that started in 2008, is one of 74 in phase 3, and was the 53rd registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing brivaracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Antiepileptic Drugs (AEDs) are the main treatment for epilepsy; however, only a limited number of AEDs are approved for use as monotherapy. The objective of this study is to evaluate the efficacy of BRV in the conversion of partial onset seizure patients from combination treatment to monotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
50 mg daily
Drug: Brivaracetam
100 mg daily
Drug: Brivaracetam
25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg \> 20 mg) for subjects not participating in the follow-up study)
Also known as: ucb 34714
25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg \> 50 mg \> 20 mg) for subjects not participating in the follow-up study)
Also known as: ucb 34714
The Cumulative Exit Rate at 112 Days After the Beginning of the Baseline Antiepileptic Drug (AED) Tapering Phase
The cumulative exit rate was estimated using Kaplan-Meier methods and was based on the duration between start of the Evaluation Period (EP) and the earliest date the first exit criterion was met for each subject. Subjects completing the EP without meeting an exit criterion were censored on Day 112. The primary comparison was BRV 50 mg/day vs a historical control. The upper limit of the 2-sided 95 % Confidence Interval for the estimate was compared to the historical lower bound estimate of 0.722.
Time frame: From Visit 4 (week 1) to the end of the Evaluation Period (week 17) (approximately 16 weeks)
This multi-Center study started to enroll subjects in August 2008 and concluded in March 2010.
| Milestone | Brivaracetam (BRV) 50 mg | Brivaracetam (BRV) 100 mg |
|---|---|---|
| Started | 47 | 15 |
| Completed | 14 | 7 |
| Not completed | 33 | 8 |
| Withdrew: Lack of efficacy | 15 | 5 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Other reason | 5 | 1 |
| Withdrew: Sae, non-fatal | 1 | 1 |
| Withdrew: Ae, non-serious non-fatal | 8 | 1 |
| Withdrew: Ae of unknown type | 1 | 0 |
The cumulative exit rate was estimated using Kaplan-Meier methods and was based on the duration between start of the Evaluation Period (EP) and the earliest date the first exit criterion was met for each subject. Subjects completing the EP without meeting an exit criterion were censored on Day 112. The primary comparison was BRV 50 mg/day vs a historical control. The upper limit of the 2-sided 95 % Confidence Interval for the estimate was compared to the historical lower bound estimate of 0.722.
| percentage of subjects | Efficacy Set (Brivaracetam 50 mg Treated Subjects) |
|---|---|
| The Cumulative Exit Rate at 112 Days After the Beginning of the Baseline Antiepileptic Drug (AED) Tapering Phase | 0.474 (0.310 to 0.638) |
Collected over Adverse Events were collected from Week 0 over the 1-week BRV Add-On Period and the 15-week Evaluation Period until the end fo Follow-Up Period (Week 23) or Early Discontinuation Visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brivaracetam (BRV) 50 mg | — | 3/47 (6.4%) | 31/47 (66%) |
| Brivaracetam (BRV) 100 mg | — | 1/15 (6.7%) | 10/15 (66.7%) |
| Event | Brivaracetam (BRV) 50 mg | Brivaracetam (BRV) 100 mg |
|---|---|---|
| ConvulsionNervous system disorders | 0/47 | 1/15 |
| Renal failure acuteRenal and urinary disorders | 0/47 | 1/15 |
| Intentional overdoseInjury, poisoning and procedural complications | 1/47 | 0/15 |
| EpilepsyNervous system disorders | 1/47 | 0/15 |
| Status epilepticusNervous system disorders | 1/47 | 0/15 |
| Suicide attemptPsychiatric disorders | 1/47 | 0/15 |
| Event | Brivaracetam (BRV) 50 mg | Brivaracetam (BRV) 100 mg |
|---|---|---|
| DizzinessNervous system disorders | 7/47 | 2/15 |
| FatigueGeneral disorders | 4/47 | 2/15 |
| Decreased appetiteMetabolism and nutrition disorders | 1/47 | 2/15 |
| ConvulsionNervous system disorders | 5/47 | 2/15 |
| DepressionPsychiatric disorders | 3/47 | 2/15 |
| IrritabilityGeneral disorders | 5/47 | 0/15 |
| AstheniaGeneral disorders | 4/47 | 0/15 |
| HeadacheNervous system disorders | 4/47 | 1/15 |
| AnxietyPsychiatric disorders | 4/47 | 0/15 |
| InsomniaPsychiatric disorders | 4/47 | 0/15 |
Baseline Characteristics refer to the Intent-to-Treat Set (ITT), consisting of all randomized subjects with at least 1 intake of study medication.
| Age, Categorical(Participants) | Brivaracetam (BRV) 50 mg | Brivaracetam (BRV) 100 mg | Total Title |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 Years | 45 | 14 | 59 |
| >=65 years | 2 | 1 | 3 |
| Age, Continuous(years) | Brivaracetam (BRV) 50 mg | Brivaracetam (BRV) 100 mg | Total Title |
|---|---|---|---|
| Mean | 39.0 ± 13.8 | 44.3 ± 15.9 | 40.3 ± 14.4 |
| Sex: Female, Male(Participants) | Brivaracetam (BRV) 50 mg | Brivaracetam (BRV) 100 mg | Total Title |
|---|---|---|---|
| Female | 27 | 11 | 38 |
| Male | 20 | 4 | 24 |
The record gives a start of Aug 2008, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 6 years 10 months after primary completion. A results delay was requested in Apr 2011.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam